Vitamin D Deficiency, Supplementation, and Risk of Mortality and Chronic Disease: Evidence from Matched Cohorts in Israel and the US

Ariel Israel[1,2]*, Abraham Weizman[3], Sarah Israel[4],

Shai Ashkenazi[5,6], Eytan Ruppin[7], Eli Magen[8], Eugene Merzon[1,5], Shlomo Vinker[1]

Affiliations:

[1] Leumit Research Institute, Leumit Health Services; Tel-Aviv, Israel

[2] Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medical & Health Sciences, Tel Aviv University; Tel-Aviv, Israel

[3] Research Unit, Geha Mental Health Center, Felsenstein Medical Research Center and Sagol School of Neurosciences, Faculty of Medical & Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.

[4] Department of Clinical Microbiology and Infectious Diseases and Department of Internal Medicine, Hadassah-Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem Israel

[5] Adelson School of Medicine, Ariel University; Ariel, Israel.

[6] Schneider Children's Medical Center, Petah-Tikva, Israel

[7] Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

[8] Medicine A Department, Assuta Ashdod University Medical Center, Ben Gurion University of the Negev; Beer Sheva, Israel

Corresponding author: Ariel Israel, Leumit Research Institute, Sprinzak 23, Tel-

Aviv 6473817, Israel, Telephone: +972-3-6970483. Fax: +972-76-8889190

Email: aisrael@leumit.co.il

Abstract word count: 147

Word count: 4,000

Tables count: 2

Figures count: 4

Abstract

Vitamin D deficiency is widespread and has been linked to adverse health outcomes, but its causal role remains debated. We analyzed data from two large healthcare networks—Leumit Health Services in Israel and the US-based TriNetX network—using matched cohort designs to compare individuals with severe vitamin D deficiency (<10 ng/mL) to those with sufficient levels (>30 ng/mL). Vitamin D showed strong seasonal variation, and deficiency was associated with increased risks of mortality, cardiovascular events, dialysis, and leg/foot amputation in both cohorts. To assess causality, we modeled serum vitamin D levels based on monthly pharmacy-dispensed supplementation and performed time-dependent Cox regressions adjusting for baseline deficiency. We identified a dose-dependent reduction in risk with supplementation associated, independent of baseline levels, with substantial absolute risk reductions. These findings support vitamin D deficiency as a modifiable risk factor and provide a rationale for targeted clinical trials in severely deficient populations.

Introduction

Vitamin D deficiency is widespread and remains a significant global public health issue, particularly among populations with limited sun exposure or darker skin pigmentation[1–3]. While its role in bone health is well established, increasing evidence has linked low serum 25-hydroxyvitamin D (25[OH]D) levels to increased mortality[4] and a wide range of chronic conditions, including diabetes[5,6], cardiovascular disease[7], retinopathy, chronic kidney disease, foot ulcers, and neurodegenerative disorders[8–13]. However, despite extensive observational research, the causality of these associations remains disputed. One major challenge is disentangling whether low vitamin D levels are a contributing factor to poor health, or merely a biomarker of existing disease or adverse health behaviors.

Israel, like many countries, has experienced persistently high rates of diabetes-related complications, including lower extremity amputations, which is particularly elevated compared to other OECD nations[14,15]. At the same time, vitamin D deficiency is common in several demographic subgroups, particularly among individuals with limited sun exposure due to lifestyle, occupational, or cultural practices. Yet, large-scale population-level studies explicitly quantifying the long-term health risks of severe vitamin D deficiency in well-matched cohorts, and investigating whether such risks are modifiable, are scarce.

In this study, we leverage the comprehensive electronic health records (EHRs) of two large and demographically distinct populations—Leumit Health Services (LHS) in Israel[16,17] and the US-based TriNetX Research Network[18]—to assess the long-term clinical implications of severe vitamin D deficiency (<10 ng/mL) compared to sufficiency (>30 ng/mL). Using tightly matched cohorts, we evaluate a broad range of clinical outcomes, including mortality,

cardiovascular events, renal failure, and diabetic complications. We then replicate these findings across both healthcare systems to ensure robustness and generalizability.

To address the causal question, we implement a two-step analytical approach. First, leveraging 15 years of historical data—including serum 25(OH)D test results and pharmacy-dispensed vitamin D supplementation records—we build a predictive model that estimates the serum impact of vitamin D supplementation based on dosage, timing, and frequency of purchased supplements. In this step, measured serum 25(OH)D levels serve as the dependent variable, allowing us to quantify the contribution of supplementation to serum levels across individuals and time. Second, we use this model to estimate, for each individual and calendar month, the expected serum contribution attributable to supplementation alone. This estimated exposure is then used as a time-dependent covariate in multivariable Cox proportional hazards models, alongside the baseline measured vitamin D level. This dual-covariate structure enables us to disentangle the confounded relationship between vitamin D as a biomarker of health status and its role as a causal factor. Specifically, by isolating the effect of supplementation—quantified monthly from individual pharmacy records and independent of patient characteristics—we demonstrate that vitamin D supplementation is independently associated with improved outcomes, even after adjusting for baseline serum levels. We further examine dose-response relationships, absolute risk reductions, and the number needed to treat (NNT), emphasizing the clinical relevance of supplementation.

Results

We began our analysis with an exploratory assessment of over 1.6 million serum 25(OH)D test results collected since 2009 from approximately 440,000 Leumit Health Services

(LHS) insurees aged 18 years or older. Serum 25(OH)D levels demonstrated pronounced seasonal variation, consistent with fluctuations in sun exposure throughout the year. The fitted model revealed a robust periodic signal (see Supplementary Table 1), with peak vitamin D levels observed in late summer and a nadir around mid-February (Figure 1A).

To normalize for seasonality, we derived a population-based normogram (Figure 1B) that maps measured vitamin D levels to their expected nadir equivalents. This calendar-adjustment procedure was applied to all serum measurements, enabling generation of a seasonally adjusted annual exposure metric for each measured vitamin D levels. We then computed the average of these calendar-adjusted levels per person to reflect long-term vitamin D status. The resulting distribution (Figure 1C) highlights a substantial prevalence of severe deficiency (<10 ng/mL) and a smaller subgroup with sufficient average levels (>30 ng/mL). Severe deficiency was substantially more common in females, a pattern that aligns with known differences in sun exposure behaviors among women in certain cultural and religious communities within the population.

LHS Matched cohort

To evaluate the clinical consequences of vitamin D status, we constructed a matched cohort comparing individuals with severe deficiency to those with sufficiency (flowchart in Supplementary Figure 1). The index date was defined as the first recorded serum 25(OH)D test for each individual from 2009 onward. Using the seasonal correction model described above, we calculated the calendar-adjusted mean vitamin D level for each person based on the index and subsequent measurements, and classified individuals into two exposure groups: severely deficient (<10 ng/mL) and sufficient (>30 ng/mL). For each severely deficient individual, we selected a matched control using 1:1 exact matching on age category, sex, socioeconomic status (SES),

geodemographic classification (general population, Arab, or Ultra-Orthodox), and body mass index (BMI) category at the index date. Among eligible controls, the individual with the closest BMI was selected. Matching on BMI at the time of vitamin D testing helped ensure comparable distributions of metabolic risk factors between groups, thereby strengthening causal inference from vitamin D serum levels comparisons.

Table 1 presents the baseline characteristics of the matched cohort, comprising 14,830 individuals with severe vitamin D deficiency (mean 25(OH)D <10 ng/mL) and 14,830 controls with sufficient levels (>30 ng/mL), matched 1:1 on sex, age category, BMI category, socioeconomic status, and ethnic group. As expected from the matching design, the two groups were balanced across all matching variables, with negligible standardized mean differences (SMD <0.01 for age and BMI). The mean age was 45 years, with 65.5% female participants in both groups. Body weight, height, and BMI were similar between groups, with only minor differences in height and blood pressure. Slightly higher systolic (123 vs. 121 mmHg) and diastolic (74.8 vs. 74.2 mmHg) blood pressures were noted in the deficient group (p<0.001), though the effect sizes were small. Smoking status differed between groups, with current smoking more prevalent among individuals with severe deficiency (21.1% vs. 16.6%, p<0.001, OR=1.34), and non-smoking more common in the sufficient group (81.4% vs. 77.1%, OR=0.77). These differences likely reflect residual behavioral or cultural factors not fully captured by matching.

Ethnic distribution (Arab, Jewish Ultra-Orthodox, and general population) and socioeconomic status were well-balanced by design, with no significant differences observed. Overall, the matched cohort provides a robust framework for assessing the clinical consequences of long-term vitamin D deficiency, while minimizing confounding by major demographic and structural variables.

We examined clinical associations with severe vitamin D deficiency in the LHS matched cohort (Supplementary table 2). Baseline associations are presented graphically as a forest plot (Figure 2A), and follow-up outcomes are illustrated using Kaplan-Meier curves (Figure 3A). Despite

140   matching on demographic and metabolic characteristics, individuals with severe vitamin D deficiency exhibited significantly higher rates of chronic conditions at baseline. Elevated odds were observed for diabetes-related and cardiovascular outcomes, including foot or toe amputation (OR 3.92, 95% CI [2.02 to 7.60], p = 5.4×10^{-5}), diabetic retinopathy (OR 1.68, 95% CI [1.44 to 1.97], p = 1.6×10^{-10}), dementia (OR 1.98, 95% CI [1.60 to 2.45], p = 2.6×10^{-10}), myocardial

145   infarction (OR 1.38, 95% CI [1.23 to 1.54], p = 4.9×10^{-8}), and heart failure (OR 1.65, 95% CI [1.40 to 1.95], p = 2.8×10^{-9}). In contrast, the odds of skin malignancy were markedly reduced (OR 0.37, 95% CI [0.24 to 0.58], p = 1.6×10^{-5}), suggesting lower cumulative skin ultraviolet (UV) exposure in the vitamin D deficient group.

TriNetX Matched cohort

150   To validate these findings, we conducted a parallel analysis in an independent population using TriNetX, a global federated health research network comprising electronic health records from over 70 healthcare organizations and more than 120 million patients. Individuals with a single serum vitamin D measurement below 10 ng/mL were compared to those with levels above 30 ng/mL, using propensity score matching based on age, sex, BMI category, African-American

155   ethnicity, obesity diagnosis, and smoking status. **Table 2B** presents the clinical comparisons, both at baseline—defined as up to 90 days after the index date—and during longitudinal follow-up. Baseline associations are visualized as a forest plot (Figure 2B), while Kaplan-Meier survival curves are shown for follow-up outcomes among individuals without the respective condition in the first 90 days (Figure 3B).

The associations observed in TriNetX were directionally consistent with those in the LHS cohort, although slightly less pronounced. This attenuation likely reflects a methodological limitation: in TriNetX, cohort classification was based on a single vitamin D measurement, whereas in LHS, individuals were categorized according to their mean vitamin D levels over time, providing a more stable estimate of long-term exposure. Here too, despite propensity score matching, individuals with severe vitamin D deficiency exhibited significantly higher odds of chronic conditions at baseline (defined as diagnoses recorded prior to and within 90 days following vitamin D testing). Baseline odds were significantly elevated for diabetes-related and cardiovascular conditions, including foot or toe amputation (OR 3.04, 95% CI [2.46 to 3.74], p = 6.2×10^{-29}), diabetic retinopathy (OR 1.67, 95% CI [1.62 to 1.72], p = 2.7×10^{-266}), and dementia (OR 1.27, 95% CI [1.22 to 1.32], p = 6.6×10^{-35}). Odds were also increased for myocardial infarction (OR 1.50, 95% CI [1.46 to 1.54], p = 2.4×10^{-181}), heart failure (OR 1.54, 95% CI [1.51 to 1.57], p < 1×10^{-308}), chronic kidney disease (OR 1.30, 95% CI [1.28 to 1.32], p < 10^{-300}), and dialysis (OR 1.60, 95% CI [1.53 to 1.67], p<10^{-103}). In contrast, the odds of skin malignancy were significantly reduced (OR 0.69, 95% CI [0.66 to 0.71], p = 6.7×10^{-87}), again suggesting lower cumulative UV skin exposure in the vitamin D–deficient group. No difference in short-term mortality was observed at baseline (OR 1.00, 95% CI [0.89 to 1.12], p = 1.00).

The consistency of these baseline differences across two large and demographically distinct cohorts reinforces the association between severe vitamin D deficiency and a broad profile of chronic disease burden not attributable to age, sex, BMI, ethnicity, or other matched covariates.

To evaluate the longitudinal impact of vitamin D status, we conducted survival analyses restricted to individuals without the outcome of interest at baseline (Figure 3). Kaplan-Meier

plots for both the LHS and TriNetX cohorts are shown in Figure 3. These curves show a consistent divergence in risk over time.

In both cohorts, all-cause mortality was significantly elevated (LHS: HR 2.74, 95% CI [2.54 to 2.96], $p < 10^{-308}$; TriNetX: HR 1.55, 95% CI [1.52 to 1.57], $p < 10^{-308}$), with survival curves separating early and continuing to diverge over time. Risks for clinical complications increased during follow-up with vitamin D deficiency. Foot or toe amputation showed the steepest increase in both cohorts (LHS: HR 4.66, 95% CI [2.88 to 7.53], $p < 10^{-11}$; TriNetX: HR 2.20, 95% CI [2.01 to 2.42], $p < 10^{-65}$), with persistent divergence over several years. Diabetic retinopathy was also more frequent among vitamin D–deficient individuals (LHS: HR 2.04, 95% CI [1.69 to 2.47], $p < 10^{-13}$; TriNetX: HR 1.89, 95% CI [1.82 to 1.96], $p < 10^{-247}$), as was dementia (LHS: HR 1.21, 95% CI [1.08 to 1.35], $p = 0.0009$; TriNetX: HR 1.18, 95% CI [1.14 to 1.21], $p < 10^{-26}$).

Cardiovascular outcomes also showed consistent associations. Myocardial infarction was more common in the deficient group (LHS: HR 1.25, 95% CI [1.09 to 1.44], $p = 0.001$; TriNetX: HR 1.43, 95% CI [1.39 to 1.46], $p < 10^{-162}$), as was heart failure (LHS: HR 1.17, 95% CI [1.04 to 1.32], $p = 0.008$; TriNetX: HR 1.42, 95% CI [1.39 to 1.45], $p < 10^{-270}$), hemodialysis (LHS: HR 2.11, 95% CI [1.32 to 3.36], $p = 0.001$; TriNetX: HR 2.45, 95% CI [2.34 to 2.55], $p < 10^{-308}$).

In contrast, the incidence of skin malignancy was consistently lower among individuals with severe vitamin D deficiency (LHS: HR 0.47, 95% CI [0.39 to 0.57], $p < 10^{-13}$; TriNetX: HR 0.69, 95% CI [0.67 to 0.72], $p < 10^{-94}$), likely reflecting reduced cumulative UV exposure in this group.

The replication of these trends in matched cohorts across two large, geographically and structurally distinct healthcare systems reinforces the robustness and biological plausibility of the observed associations. The striking similarity in magnitude, direction, and timing of risk

divergence across datasets provides strong support for a causal role of severe vitamin D deficiency in chronic disease progression and mortality.

Isolating supplementation effect

210   To assess whether vitamin D is a modifiable risk factor, we investigated the effect of supplementation on serum levels and downstream clinical outcomes. We began by decomposing the variation in serum 25(OH)D levels into two components: one attributable to largely non-modifiable demographic and structural factors—such as BMI, sex, ethnicity, and socioeconomic status—and another potentially modifiable through supplementation. Using a multivariable linear

215   regression model on over 1.4 million observations, we predicted log-transformed 25(OH)D levels based on sex, ethnic group, socioeconomic status, BMI category, age, and seasonal harmonics. This model explained 25.5% of the variance in serum vitamin D levels ($R^2 = 0.255$) in the population, with notably strong negative associations observed for Arab females and individuals with higher BMI (Supplementary Table 3).

220   To isolate the contribution of vitamin D supplementation, we quantified the total intake in international units (IU) from all vitamin D products purchased through LHS pharmacies during the 4 months preceding each vitamin D test, as well as over quarterly and yearly periods. We then regressed the residuals from the demographic model on estimated supplementation amounts. Supplement use in the two months prior to testing had the strongest effect (coef = 0.032 per 1000

225   IU, $p<10^{-300}$), with diminishing impact for more distant time windows (Supplementary Table 4). Together, supplementation variables explained an additional 9.3% of the variance in vitamin D levels not captured by baseline characteristics, demonstrating a quantifiable effect of supplement use on serum vitamin D.

Survival analyses incorporating supplementation

230   To evaluate the impact of vitamin D supplementation on survival outcomes, we analyzed all Leumit Health Services (LHS) members aged 30 years or older with at least one serum 25(OH)D measurement recorded since 2009, using the date of first measurement as the index date. Two key exposure variables were defined: (1) baseline serum 25(OH)D concentration, calendar-adjusted and categorized as <5, 5–10, 10–15, and 15–20 ng/mL; and (2) vitamin D

235   supplementation, modeled as a time-dependent covariate reflecting the predicted monthly increase in serum 25(OH)D based on pharmacy purchase data. Supplementation levels were updated monthly, with the reference category defined as no supplementation or an estimated effect below 0.2 ng/mL.

    We fitted multivariable Cox proportional hazards models for all-cause mortality and key

240   clinical outcomes, adjusting for age, sex, BMI category, smoking status, and socioeconomic status (SES). Results are presented in Figure 4.

    For **mortality** (Figure 4A), baseline vitamin D deficiency was associated with increased risk in a graded, dose-dependent fashion: HR=1.375 [1.298–1.456] for <5 ng/mL; HR=1.278 [1.223–1.335] for 5–10 ng/mL; HR=1.084 [1.039–1.132] for 10–15 ng/mL. Vitamin D

245   supplementation was independently protective, with a graded effect depending on the supplementation level: the strongest effect observed for individuals and during periods in which predicted serum increases exceeded 20 ng/mL (HR=0.331 [0.314–0.348]), and significant risk reductions were also seen at lower supplementation levels—for example, HR=0.403 [0.387–0.419] for predicted increases between 0.2 and 10 ng/mL.

250   These findings support a causal interpretation: lower baseline vitamin D levels confer

increased risk, while supplementation—modeled independently of baseline health status—

attenuates that risk in a dose-dependent manner.

We applied the same Cox regression framework to additional clinical outcomes. Low

baseline serum vitamin D levels were associated with significantly elevated hazards for nearly all

255   endpoints, including mortality, diabetes, diabetic retinopathy, myocardial infarction, and foot or

toe amputation. Vitamin D supplementation, modeled as a time-dependent variable based on

pharmacy data and estimated serum impact, was consistently associated with substantial risk

reduction across outcomes.

Diabetes Mellitus (Figure 4B): Low baseline 25(OH)D levels were strongly associated

260   with increased diabetes risk in a clear dose-dependent fashion, with HR=1.64 [1.54–1.75] for <5

ng/mL, HR=1.45 [1.39–1.53] for 5–10 ng/mL, HR=1.33 [1.27–1.39] for 10–15 ng/mL, HR=1.16

[1.11–1.22] for 15–20 ng/mL (all $p<10^{-9}$). Conversely, all supplementation categories were

associated with significantly lower diabetes risk, e.g. HR=0.71 [0.68–0.73] in the 0.2–10 ng/mL

group. All p-values were $<10^{-38}$, indicating strong statistical significance.

265   **Diabetic Retinopathy** (Figure 4C): Baseline vitamin D levels exhibited a strong inverse

association with risk of diabetic retinopathy, ranging from HR=1.20 [1.05–1.37] for 15–20

ng/mL to HR=3.03 [2.61–3.51] for levels below 5 ng/mL. Vitamin D supplementation was

consistently protective across all strata, with an HR of 0.74 [0.68–0.80] in the 0.2–10 ng/mL

predicted increase group and even greater reductions in risk for increases above 20 ng/mL.

270   **Myocardial Infarction** (Figure 4D): Low baseline 25(OH)D levels were associated with

increased risk of myocardial infarction, with hazard ratios ranging from 1.14 [1.05–1.23] for 15–

20 ng/mL to 1.45 [1.29–1.63] for <5 ng/mL. Vitamin D supplementation again demonstrated a

strong, dose-dependent protective effect, with HR=0.73 [0.69–0.77] for predicted increases of

0.5–10 ng/mL, HR=0.70 [0.64–0.77] for 5–10 ng/mL, and HR=0.63 [0.57–0.70] for increases above 20 ng/mL (all $p<10^{-13}$).

Foot/Toe Amputation (Figure 4E): Severe vitamin D deficiency was associated with markedly elevated risk of lower extremity amputation, with HR=4.41 [3.08–6.33] for <5 ng/mL and HR=1.73 [1.28–2.34] for 10–15 ng/mL. A strong dose-response gradient was evident. Supplementation was associated with a reduced risk , though only the 0.5–10 ng/mL group reached statistical significance—likely due to limited power resulting from the small number of amputation events.

Skin Malignancy (Figure 4F): While baseline serum 25(OH)D levels were inversely associated with the risk of skin malignancy in a graded fashion, vitamin D supplementation showed no significant effect. Hazard ratios across all supplementation categories remained close to 1.0, with non-significant *p*-values. This null finding provides a useful negative control, reinforcing the specificity of our supplementation variable and reducing the likelihood that the observed protective associations with other outcomes are driven by residual confounding or reverse causation.

These findings indicate that vitamin D supplementation is independently and strongly associated with reduced risk of multiple adverse outcomes, even after adjusting for baseline vitamin D levels and demographic confounders. The consistent, monotonic pattern in mortality, cardiovascular, and metabolic endpoints strongly supports a modifiable, causal role for vitamin D status in chronic disease prevention.

Risk Reduction and Number Needed to Treat

To evaluate the clinical utility of vitamin D supplementation, we estimated the 10-year number needed to treat (NNT) to prevent all-cause mortality and incident diabetes mellitus,

stratified by age (individuals over 30, 50, and 70 years), baseline serum 25(OH)D level, and the predicted impact of supplementation on serum levels (Figure 5).

For all-cause mortality, NNTs decreased markedly with age. Among individuals with baseline 25(OH)D levels <10 ng/mL, NNTs dropped from 60.3–89.8 from age 30, to 18.4–29.8 from age 50, and as low as 3.5–5.4 from age 70 depending on supplementation dose. This pattern reflects the increasing absolute mortality risk with age and highlights the particularly strong preventive potential of supplementation in older adults, even moderately deficient.

For incident diabetes mellitus, NNTs were consistently low across all age groups and relatively stable across strata of baseline vitamin D status and supplementation level. Among individuals with 25(OH)D <10 ng/mL, NNTs ranged from 16.2 to 21.6 over age 30, 12.2 to 15.8 over age 50, and 15.1 to 29.7 age 70. These findings suggest that even modest increases in serum vitamin D levels can translate to meaningful reductions in diabetes incidence across the lifespan.

Collectively, these results show that vitamin D supplementation may confer substantial clinical benefit, particularly among those with severe deficiency and at older ages. The persistently low NNTs for diabetes across all ages also support early and sustained intervention to mitigate long-term metabolic risk.

Discussion

In this dual-cohort large-scale observational study leveraging real-world data from over 120 million patients in two countries, we demonstrate that long-term vitamin D deficiency is strongly associated with elevated risks of mortality, metabolic disease, cardiovascular events, and microvascular complications. Importantly, our analyses suggest that vitamin D supplementation,

modeled through pharmacy records and validated serum responses, is associated with significant reductions in risk across a wide range of clinical outcomes. The protective associations were consistent, dose-dependent, and remained significant despite tight baseline matching and adjustment for BMI, demographic, ethnic, and socioeconomic factors.

The cohort design allowed for tight baseline matching on modifiable risk factors, including BMI and socioeconomic status. Findings were replicated in an independent, US-based federated health network (TriNetX), enhancing external validity. A major strength of this study is the integration of detailed laboratory, demographic, and pharmacy data from a national health organization, enabling precise classification of baseline vitamin D status and estimation of serum responses to supplementation. We leveraged these data to construct a time-dependent covariate for vitamin D supplementation, based on pharmacy purchase records and calibrated to predict serum level changes. This approach enabled us to distinguish the modifiable effect of supplementation from the confounding influence of demographic, socioeconomic, and BMI-related determinants of vitamin D deficiency. This innovative analysis identified a strong, graded association between supplementation and improved outcomes, even after adjustment for a wide range of potential confounders.

Our findings revealed remarkably low numbers needed to treat (NNTs) for major outcomes, including all-cause mortality and new-onset diabetes, particularly among individuals with baseline 25(OH)D levels below 10 ng/mL. In older adults with severe deficiency, NNTs for preventing mortality approached 5—an exceptionally favorable value that compares favorably with, and in some cases exceeds, the effectiveness of established pharmacologic prevention strategies such as statins or antihypertensive therapy in moderate-risk populations. Even moderate supplementation (e.g., predicted increases of 10–20 ng/mL) in these individuals yielded

NNTs well below 20, highlighting a substantial absolute benefit. Importantly, the impact was not limited to the severely deficient: individuals with baseline serum 25(OH)D levels between 10–20 ng/mL also derived clinically meaningful benefit, with consistently low NNTs for both mortality and diabetes prevention. These results suggest that vitamin D supplementation may offer a scalable, low-cost intervention with considerable public health potential, particularly when targeted to populations with suboptimal baseline levels.

While prior randomized controlled trials of vitamin D supplementation have produced mixed results[19–22], many of these studies were constrained by short follow-up, underpowered sample sizes, enrollment of vitamin D-replete individuals, or subtherapeutic dosing. In contrast, our real-world approach captures long-term effects in populations with a broad range of vitamin D deficiency and treatment adherence, better reflecting the complexity of clinical practice.

The biological mechanisms underlying these protective effects remain to be fully elucidated. One plausible pathway involves modulation of the human microbiome—either through direct immune effects or by altering microbial or protozoal species that drive chronic inflammation, insulin resistance, or tissue injury[23–28]. Supporting this hypothesis is the breadth of conditions impacted—including diabetes, cardiovascular disease, and all-cause mortality—which may share common microbial or immune-mediated origins. A particularly notable observation was the significant reduction in foot and toe amputations among supplemented individuals. Given that such amputations are frequently precipitated by persistent infection, this finding further supports a microbiologically mediated mechanism[29]. The historically high rate of amputations observed in Israel has remained inadequately explained; our findings suggest that severe vitamin D deficiency, which is disproportionately prevalent in certain population subgroups, may contribute to this excess risk.

This study has limitations. As an observational analysis, residual confounding cannot be entirely excluded, despite extensive matching and multivariable adjustment. Vitamin D supplementation may co-occur with other unmeasured health-promoting behaviors. Furthermore, our exposure definition relied on pharmacy purchase data, which may not capture over-the-counter supplementation obtained through untracked channels. However, the strength, consistency, and dose-dependent nature of the associations across two independent cohorts argue strongly for a true underlying effect.

In conclusion, our findings provide compelling evidence that vitamin D deficiency is a major and modifiable risk factor for morbidity and mortality. Vitamin D supplementation represents a low-cost, low-risk intervention with broad preventive potential. Treating deficiency in high-risk groups should be a public health priority. Given the magnitude of benefit and minimal downside, vitamin D supplementation may be one of the most cost-effective strategies to improve population health.

Online Methods

Study Population and Data Sources

380   We used de-identified electronic health records (EHRs) from Leumit Health Services (LHS), a

nationwide Israeli health maintenance organization. The dataset included demographics, clinical

diagnoses (ICD-9), laboratory test results, pharmacy purchases, and follow-up information. Adult

patients aged 50 and older who had at least one serum 25(OH)D measurement between 2009 and

2014 were eligible for inclusion. The date of the first serum 25(OH)D value served as the index

385   date for each individual.

To validate findings, we used the TriNetX US Collaborative Network, which aggregates de-

identified EHRs from over 70 health care organizations (HCOs), including diagnoses, laboratory

results, prescriptions, and procedures. The TriNetX platform enables prospective-style

retrospective analyses using standardized temporal alignment.

390   ## Seasonal Normalization of Serum Vitamin D

Vitamin D levels display marked seasonal variation. To standardize values across measurement

dates, we fitted a sinusoidal regression model using log-transformed 25(OH)D values with first-

and second-order sine and cosine terms to model annual periodicity:

$$\log(\text{VitaminD}) \sim \beta_0 + \beta_1 \sin t + \beta_2 \cos t + \beta_3 \sin 2t + \beta_4 \cos 2t$$

where t denotes the day of the year in radians. Adjusted values were derived by estimating serum

395   levels at the population nadir (February 14) and removing seasonal effects using the fitted model.

Each patient's nadir was defined as the lowest calendar-adjusted serum value between 2009 and 2014.

Data Extraction and Preprocessing

Structured EHR data were queried using T-SQL. Python 3.11 and the Pandas library were used for data preprocessing. Each patient record was anonymized using an internal study ID. Baseline covariates, including sex, age, BMI category, socioeconomic status, ethnicity, and smoking status, were extracted as of the index date.

Medical conditions were defined based on diagnosis codes and lab thresholds. An exploratory analysis was performed using a curated list of ~200 common conditions developed at the Leumit Research Institute.

Matched Cohort Construction (LHS)

To evaluate the long-term impact of severe deficiency, we constructed a 1:1 matched cohort of individuals with calendar-adjusted vitamin D levels <10 ng/mL and those with >30 ng/mL. Matching was exact on: age category, sex, BMI category, ethnic sector (general, Arab, ultra-Orthodox), socioeconomic status, year of LHS enrollment.
This ensured balance in major demographic and metabolic risk factors.

TriNetX Validation Cohort

For external validation, we compared TriNetX patients with 25(OH)D <10 ng/mL to those with >30 ng/mL. Propensity score matching was performed on: age, sex, African American ethnicity,

415 BMI category, obesity diagnosis, smoking status. Post-matching balance was assessed using standardized mean differences.

Vitamin D supplementation estimation

All vitamin D–containing product purchases were extracted from Leumit Health Services (LHS) pharmacy records. Each product in the catalog was assigned a total vitamin D content (expressed
420 in kilo–international units, kIU) based on its labeled concentration and the number of dosage units per package.

To quantify the contribution of supplementation to serum 25-hydroxyvitamin D [25(OH)D] levels, we implemented a two-stage regression framework:

1. **Baseline Model**: A multivariable linear regression was used to predict log-transformed
425 serum 25(OH)D levels based on demographic and structural variables, including age, sex, BMI category, ethnicity, socioeconomic status, and seasonal harmonics (sine and cosine terms for date). This model explained 25.5% of the variance in serum 25(OH)D levels.

2. **Supplementation Model**: The residuals from the baseline model were regressed on lagged vitamin D supplement purchases. Total purchased vitamin D (in kIU) was
430 aggregated across time bins—1 month, 3 months (quarter), and 12 months (year) preceding the test date. Each time bin was assigned an empirically estimated coefficient reflecting its weighted contribution to the serum level at the target date.

Validation of Supplementation Model and Avoidance of Reverse Causation

Although clinical factors such, as impaired renal function, may influence vitamin D
435 metabolism, no clinical or demographic variables were included in the supplementation model to

avoid potential reverse causation. The baseline model, which predicted log-transformed serum 25(OH)D levels using demographic and temporal variables, explained 25.5% of the total variance. The second-stage model, which incorporated only weighted vitamin D supplementation exposures based on pharmacy purchase data, explained an additional 9.3% of the residual variance. Together, the two-stage model accounted for ~35% of the variance in serum 25(OH)D, providing strong internal validation and confirming the measurable, dose-dependent impact of documented supplementation.

Classification of Vitamin D Status

Baseline vitamin D status was defined using the first calendar-adjusted serum 25(OH)D measurement per individual, grouped into the following categories: 0–5 ng/mL, 5–10 ng/mL, 10–15 ng/mL, 15–20 ng/mL, and >20 ng/mL (reference category). For each individual and each calendar month from the index date to censoring, we estimated the serum contribution of vitamin D supplementation, expressed in ng/mL equivalents. These values were grouped into supplementation exposure categories: 0–0.2 ng/mL (reference), 0.2–10 ng/mL, 10–20 ng/mL, and >20 ng/mL. This time-varying covariate was incorporated into Cox proportional hazards models to evaluate the independent effects of supplementation.

Survival Analysis Using Time-Dependent Supplementation

Time-dependent Cox proportional hazards models were used to evaluate the effect of supplementation on mortality and disease outcomes. Monthly intervals were created per patient, updating the supplementation covariate dynamically.

Covariates included age, sex, smoking status, BMI category, and SES. Analyses were stratified by baseline vitamin D status to assess effect modification.

Absolute Risk Reduction and Number Needed to Treat (NNT)

ARR and NNT were calculated for 10 years:

1. **Stratification**: Individuals were grouped by baseline vitamin D status.

2. **Time-Dependent Cox Model**: Fitted with time-updated supplementation bins.

3. **Reference Profile**: Defined using mean values from the <0.5 ng/mL supplementation group.

4. **Survival Estimation**: Baseline and supplemented survival probabilities were computed.

5. **ARR and NNT Calculation**:

   o $ARR(t) = S1(t) - S0(t)$

   o $NNT(t) = 1 / |ARR(t)|$

These were estimated per supplementation category and vitamin D stratum.

Statistical Analyses

470 Categorical variables were compared using Fisher's exact test. Continuous variables used two-sample t-tests. Logistic regression was used for odds ratios (ORs) with 95% confidence intervals (CIs). Longitudinal outcomes were analyzed with Cox proportional hazards models. Kaplan-Meier curves were used to visualize survival.

All analyses were performed using R 4.4 and Python 3.11.

Generative AI statement

475   ChatGPT (version 4o, OpenAI) was used to assist with language refinement for improved clarity

and flow, and to provide support with coding tasks related to data analysis scripts. All content

was reviewed and verified by the authors to ensure accuracy and integrity.

Ethics Statement

480   All LHS data were analyzed retrospectively and anonymously under IRB approval (LEU-0020-

24), with a waiver of informed consent.

TriNetX data are de-identified and analyzed under agreements with participating health

organizations, compliant with HIPAA and institutional guidelines.

Acknowledgements

Funding

This study was funded internally by Leumit Health Services. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.

Conflict of Interest

The authors have declared that there are no conflicts of interest in relation to the subject of this study.

References

1.   Hilger, J. *et al.* A systematic review of vitamin D status in populations worldwide. *British Journal of Nutrition* **111**, 23–45 (2014).

2.   Holick, M. F. Vitamin D Deficiency. *New England Journal of Medicine* **357**, 266–281 (2007).

3.   Cashman, K. D. *et al.* Vitamin D deficiency in Europe: pandemic? *Am J Clin Nutr* **103**, 1033–1044 (2016).

4.   Gotsman, I. *et al.* Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. *Eur J Heart Fail* **14**, 357–366 (2012).

5.   Scragg, R. *et al.* Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. *Diabetes Res Clin Pract* **27**, 181–188 (1995).

6. Pittas, A. G., Lau, J., Hu, F. B. & Dawson-Hughes, B. The Role of Vitamin D and Calcium in Type 2 Diabetes. A Systematic Review and Meta-Analysis. *J Clin Endocrinol Metab* **92**, 2017–2029 (2007).

510 7. Judd, S. E. & Tangpricha, V. Vitamin D deficiency and risk for cardiovascular disease. *Am J Med Sci* **338**, 40–4 (2009).

8. Usluogullari, C. A. *et al.* The relationship between microvascular complications and vitamin D deficiency in type 2 diabetes mellitus. *BMC Endocr Disord* **15**, 33 (2015).

9. Liu, L. C. Y. *et al.* Vitamin D status and outcomes in heart failure patients. *Eur J Heart*
515 *Fail* **13**, 619–625 (2011).

10. Usluogullari, C. A. *et al.* The relationship between microvascular complications and vitamin D deficiency in type 2 diabetes mellitus. *BMC Endocr Disord* **15**, 33 (2015).

11. Liu, L. *et al.* The role of vitamin D in diabetic foot ulcer; an umbrella review of meta-analyses. *Front Nutr* **11**, (2024).

520 12. Afzal, S., Bojesen, S. E. & Nordestgaard, B. G. Low 25-Hydroxyvitamin D and Risk of Type 2 Diabetes: A Prospective Cohort Study and Metaanalysis. *Clin Chem* **59**, 381–391 (2013).

13. Vasdeki, D. *et al.* Vitamin D Supplementation: Shedding Light on the Role of the Sunshine Vitamin in the Prevention and Management of Type 2 Diabetes and Its
525 Complications. *Nutrients* **16**, 3651 (2024).

14. Diabetes-Related Lower Extremity Amputation Rates per 100,000 Population | Commonwealth Fund. https://www.commonwealthfund.org/international-health-policy-center/system-stats/diabetes-related-lower-extremity-amputation?utm_source=chatgpt.com.

530   15.   OECD Reviews of Health Care Quality. OECD Reviews of Health Care Quality: Israel, raising   standards. *https://www.oecd.org/content/dam/oecd/en/publications/reports/2012/10/oecd-reviews-of-health-care-quality-israel-2012_g1g1fd99/9789264029941-en.pdf* (2012).

16.   Israel, A. *et al.* Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection:
535   test negative design study. *The BMJ* **375**, e067873 (2021).

17.   Israel, A. *et al.* Type 2 Diabetes in Patients with G6PD Deficiency. *New England Journal of Medicine* **391**, 568–569 (2024).

18.   Palchuk, M. B. *et al.* A global federated real-world data and analytics platform for research. *JAMIA Open* **6**, (2023).

540   19.   Zittermann, A. *et al.* Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000□IU vitamin D daily. *Eur Heart J* **38**, 2279–2286 (2017).

20.   Davidson, M. B., Duran, P., Lee, M. L. & Friedman, T. C. High-Dose Vitamin D Supplementation in People With Prediabetes and Hypovitaminosis D. *Diabetes Care* **36**,
545   260–266 (2013).

21.   Chen, L. *et al.* Vitamin D supplementation can improve the 28-day mortality rate in patients with sepsis-associated acute kidney injury. *Ren Fail* **46**, (2024).

22.   Zhang, Y. *et al.* Association between vitamin D supplementation and mortality: systematic review and meta-analysis. *BMJ* l4673 (2019) doi:10.1136/bmj.l4673.

550   23.   Rasheed, Z. *et al.* Toxoplasmosis in immunocompetent Saudi women: Correlation with vitamin D. *Women's Health* **17**, (2021).

24.   Schwalfenberg, G. K. A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. *Mol Nutr Food Res* **55**, 96–108 (2011).

555   25.   Merzon, E. *et al.* Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. *FEBS Journal* **287**, 3693–3702 (2020).

26.   Israel, A. *et al.* Vitamin D deficiency is associated with higher risks for SARS-CoV-2 infection and COVID-19 severity: a retrospective case–control study. *Intern Emerg Med*

560   **17**, 1053–1063 (2022).

27.   Lagishetty, V., Liu, N. Q. & Hewison, M. Vitamin D metabolism and innate immunity. *Mol Cell Endocrinol* **347**, 97–105 (2011).

28.   Singh, P., Rawat, A., Alwakeel, M., Sharif, E. & Al Khodor, S. The potential role of vitamin D supplementation as a gut microbiota modifier in healthy individuals. *Sci Rep* **10**,

565   21641 (2020).

29.   Joshi, M. *et al.* Modulatory role of vitamins A, B3, C, D, and E on skin health, immunity, microbiome, and diseases. *Pharmacological Reports* **75**, 1096–1114 (2023).

Author contributions:

Conceptualization: AI, EMe, EMa

Methodology: AI, EMe

Investigation: AI, SI, EMe

Writing – original draft: AI

Writing – review & editing: AI, AW, SI, SA, SV, EMa, EMe

Materials & Correspondence: Correspondence and requests for materials should be addressed to AI

Funding: This research was internally funded by Leumit Health Services (LHS) and was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research.The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Conflict of Interest Statement: The Authors declare that there are no conflicts of interest in relation to the subject of this study.

Abstract:

590   aOR: adjusted Odds Ratio

BMI: Body Mass Index

BP: Blood pressure

CNS: Central nervous system

EHR: Electronic health records

595   HR: Hazard Ratio

ICD-9: International Classification of Diseases, Ninth Revision

LHS: Leumit Health Services

OR: Odds Ratio

PO: Per os

600   PSM: Propensity score matching

SES: Socioeconomic status

SMD: Standardized Mean Difference

Table 1. Demographic and clinical characteristics of the study cohort at index date

		Case Vit D<10 N= 14,830	Control Vit D>30 N= 14,830	P-value	Odds Ratio	SMD
N		14,830	14,830			
Gender	**Female**	9,714 (65.5 %)	9,714 (65.5 %)	1.000	1.00 [0.95 to 1.05]	
	Male	5,116 (34.5 %)	5,116 (34.5 %)	1.000	1.00 [0.95 to 1.05]	
Age (years)		45.0 ± 18.5	45.0 ± 18.5	0.992		<0.001
Weight (kg)		72.0 ± 17.3	72.3 ± 17.1	0.170		-0.016
	~missing~	13 (0.088 %)	15 (0.101 %)		0.87 [0.38 to 1.95]	
Height (cm)		165 ± 10	165 ± 10	<0.001		-0.051
	~missing~	1,070 (7.22 %)	1,192 (8.04 %)		0.89 [0.82 to 0.97]	
BMI (kg/m2)		26.5 ± 5.7	26.4 ± 5.7	0.305		0.012
	~missing~	783 (5.28 %)	906 (6.11 %)		0.86 [0.78 to 0.95]	
BMI category	**<18.5 Underweight**	648 (4.61 %)	673 (4.83 %)	0.398	0.95 [0.85 to 1.07]	
	18.5-24.9 Normal	5,506 (39.20 %)	5,467 (39.26 %)	0.912	1.00 [0.95 to 1.05]	
	25-29.9 Overweight	4,470 (31.82 %)	4,411 (31.68 %)	0.807	1.01 [0.96 to 1.06]	
	>=30 Obese	3,423 (24.37 %)	3,373 (24.22 %)	0.780	1.01 [0.95 to 1.06]	
	~missing~	783 (5.28 %)	906 (6.11 %)	0.002	0.86 [0.78 to 0.95]	
BP systolic (mmHg)		123 ± 19	121 ± 16	<0.001		0.087
	~missing~	178 (1.20 %)	56 (0.38 %)		3.21 [2.36 to 4.41]	
BP diastolic (mmHg)		74.8 ± 10.4	74.2 ± 9.8	<0.001		0.053
	~missing~	178 (1.20 %)	57 (0.38 %)		3.15 [2.32 to 4.32]	
Smoking status	**Non-smoker**	10,771 (77.06 %)	11,901 (81.41 %)	<0.001	0.77 [0.72 to 0.81]	
	Past smoker	261 (1.87 %)	292 (2.00 %)	0.440	0.93 [0.79 to 1.11]	
	Smoker	2,946 (21.08 %)	2,426 (16.59 %)	<0.001	1.34 [1.26 to 1.43]	
	~missing~	852 (5.75 %)	211 (1.42 %)	<0.001	4.22 [3.62 to 4.94]	
Ethnic group	**Arab**	2,820 (19.0 %)	2,820 (19.0 %)	1.000	1.00 [0.94 to 1.06]	
	General	8,725 (58.8 %)	8,725 (58.8 %)	1.000	1.00 [0.95 to 1.05]	
	Jewish Ultra-orthodox	3,285 (22.2 %)	3,285 (22.2 %)	1.000	1.00 [0.95 to 1.06]	
Socio-economic status (1-20)		8.10 ± 3.61	8.18 ± 3.56	0.055		-0.023
	~missing~	711 (4.79 %)	711 (4.79 %)		1.00 [0.90 to 1.11]	

SMD: Standardized Mean Difference (Cohen's D)

Figure 1: Seasonal Variation and Population Distribution of Serum 25(OH)D Levels in LHS

A Seasonal variation regression in LHS

B Normogram of seasonal variation

C Distribution of nadir vitamin D levels in LHS population by sex

(A) Modeled seasonal fluctuation in serum vitamin D (25(OH)D) levels across the calendar year in the Leumit Health Services (LHS) population, showing a sinusoidal pattern with a nadir in mid-February and peak in late August. The 95% confidence interval is shown but appears nearly indistinguishable due to the large population size.
(B) Normogram translating observed 25(OH)D levels to their expected nadir values based on date of measurement, enabling standardization of vitamin D status across seasons.
(C) Sex-stratified distribution of mean nadir-adjusted vitamin D levels in the LHS population. Severe deficiency

(<10 ng/mL) is substantially more common in females (20.6%) than in males (10.1%), whereas vitamin D sufficiency (>30 ng/mL) is uncommon in both sexes.

Figure 2: Prevalence of Chronic Conditions at Index Date by Vitamin D Status in Two Independent Cohorts

A   Conditions present at index date in LHS

Condition before	case	control		OR [95% CI]	P value
Foot/Toe Amputation	0.29%	0.07%		3.92 [1.99-8.43]	$p < 10^{-4}$
Diabetes Mellitus	15.64%	13.22%		1.22 [1.14-1.30]	$p < 10^{-8}$
Diabetic Retinopathy	2.77%	1.67%		1.68 [1.43-1.98]	$p < 10^{-9}$
Dementia	1.73%	0.88%		1.98 [1.59-2.46]	$p < 10^{-9}$
Myocardial Infarction	4.83%	3.55%		1.38 [1.23-1.55]	$p < 10^{-7}$
Heart Failure	2.53%	1.54%		1.65 [1.40-1.96]	$p < 10^{-8}$
Kidney Disease	1.60%	1.67%		0.96 [0.80-1.15]	$p = 0.68$
Dialysis	0.05%	0.04%		1.17 [0.34-4.20]	$p = 1.00$
Skin Malignancy	0.34%	0.75%		0.45 [0.31-0.63]	$p < 10^{-5}$

B   Conditions present at index date in TriNetX

Condition before	case	control		OR [95% CI]	P value
Amputation Foot	0.09%	0.03%		3.04 [2.46 to 3.74]	$p < 10^{-28}$
Diabetes Mellitus	22.32%	18.24%		1.29 [1.27 to 1.30]	$p < 10^{-308}$
Diabetic Retinopathy	2.94%	1.78%		1.67 [1.62 to 1.72]	$p < 10^{-265}$
Dementia	1.41%	1.11%		1.27 [1.22 to 1.32]	$p < 10^{-34}$
Myocardial Infarction	3.09%	2.09%		1.50 [1.45 to 1.54]	$p < 10^{-180}$
Heart Failure	7.82%	5.22%		1.54 [1.51 to 1.57]	$p < 10^{-308}$
Kidney Disease	12.70%	10.06%		1.30 [1.28 to 1.32]	$p < 10^{-300}$
Hemodialysis	1.33%	0.83%		1.60 [1.53 to 1.67]	$p < 10^{-103}$
Skin Malignancy	1.12%	1.62%		0.68 [0.66 to 0.71]	$p < 10^{-86}$

(A) Odds ratios (OR) and 95% confidence intervals for preexisting conditions at cohort entry in the Leumit Health Services (LHS) matched cohort, comparing individuals with severe vitamin D deficiency (<10 ng/mL) to those with sufficient levels (>30 ng/mL).
(B) Corresponding analysis from the TriNetX propensity-matched cohort.

Conditions such as diabetes mellitus, diabetic retinopathy, dementia, myocardial infarction, and heart failure were consistently more prevalent in the vitamin D–deficient groups across both datasets. Foot/toe amputations showed the strongest association. In contrast, skin malignancy was significantly less common among individuals with low vitamin D, likely reflecting reduced cumulative UV exposure. These robust and replicated imbalances underscore the biological relevance of vitamin D status beyond demographic and behavioral confounding.

Figure 3: Kaplan-Meier survival and cumulative incidence curves

Kaplan-Meier survival and cumulative incidence curves comparing individuals with mean serum 25(OH)D levels below 10 ng/mL versus above 30 ng/mL across two independent cohorts: Leumit Health Services (LHS, left panels) and TriNetX (right panels). Outcomes include all-cause mortality (A-B), foot/toe amputation (C-D), diabetic retinopathy (E-F), dementia (G-H), myocardial infarction (I-J), heart failure (K-L), dialysis initiation (M-N), and skin malignancy (O-P).

Hazard ratios (HRs), 95% confidence intervals (CIs), and p-values were derived from Cox proportional hazards models in propensity-score matched cohorts. Time axis represents follow-up duration from index vitamin D measurement in years. Numbers at risk are shown below each plot for both exposure groups.

Across nearly all outcomes, individuals with low vitamin D exhibited significantly higher cumulative incidence, reinforcing the robustness and reproducibility of findings between health systems. Skin malignancy displayed an inverse pattern, likely reflecting lower cumulated UV exposure in the vitamin D deficient group.

A Mortality LHS

HR = 2.74
CI [2.54 to 2.96]
$p < 10^{-308}$

- mean Vitamin D < 10ng/mL
- mean Vitamin D > 30ng/mL

LHS Numbers at risk

VD<10	14,789	13,981	13,342	12,672	11,949	10,512	9,148	8,101	7,119
VD>30	14,784	14,632	14,464	14,225	13,921	12,714	11,482	10,414	9,487

B Mortality TriNetX

HR = 1.55
CI [1.52 to 1.57]
$p < 1 \times 10^{-308}$

- Vitamin D < 10 ng/mL
- Vitamin D > 30 ng/mL

TriNetX Numbers at risk

VD<10	403,815	293,616	253,538	222,331	193,122	168,609	146,107	122,671	98,730
VD>30	408,274	312,888	264,190	219,495	181,428	151,037	125,247	99,972	76,306

C Foot/Toe amputation LHS

HR = 4.66
CI [2.88 to 7.53]
$p < 10^{-11}$

- mean Vitamin D < 10ng/mL
- mean Vitamin D > 30ng/mL

LHS Numbers at risk

VD<10	14,746	13,923	13,289	12,617	11,898	10,464	9,109	8,064	7,086
VD>30	14,773	14,620	14,451	14,212	13,906	12,695	11,467	10,396	9,473

D Foot/Toe amputation TriNetX

HR = 2.20
CI [2.01 to 2.42]
$p < 10^{-65}$

- Vitamin D < 10 ng/mL
- Vitamin D > 30 ng/mL

TriNetX Numbers at risk

VD<10	409,463	336,767	290,799	255,005	221,504	193,389	167,580	140,700	113,240
VD>30	410,384	343,042	289,650	240,648	198,912	165,593	137,317	109,607	83,660

E Diabetic retinopathy LHS

HR = 2.04
CI [1.69 to 2.47]
$p < 10^{-13}$

- mean Vitamin D < 10ng/mL
- mean Vitamin D > 30ng/mL

LHS Numbers at risk

VD<10	14,378	13,551	12,927	12,259	11,534	10,135	8,809	7,787	6,831
VD>30	14,537	14,373	14,192	13,946	13,635	12,435	11,225	10,171	9,256

F Diabetic retinopathy TriNetX

HR = 1.89
CI [1.82 to 1.96]
$p < 10^{-247}$

- Vitamin D < 10 ng/mL
- Vitamin D > 30 ng/mL

TriNetX Numbers at risk

VD<10	398,188	328,188	283,391	248,509	215,861	188,462	163,311	137,116	110,355
VD>30	403,916	338,097	285,475	237,180	196,045	163,206	135,338	108,027	82,454

G Dementia LHS

HR = 1.21
CI [1.08 to 1.35]
$p = 0.0009$

- mean Vitamin D < 10ng/mL
- mean Vitamin D > 30ng/mL

LHS Numbers at risk

VD<10	14,532	13,700	13,035	12,361	11,642	10,243	8,908	7,876	6,932
VD>30	14,653	14,471	14,270	13,998	13,672	12,456	11,205	10,140	9,219

H Dementia TriNetX

HR = 1.18
CI [1.14 to 1.21]
$p < 10^{-26}$

- Vitamin D < 10 ng/mL
- Vitamin D > 30 ng/mL

TriNetX Numbers at risk

VD<10	426,986	347,826	301,139	264,559	230,544	201,708	175,581	148,599	120,761
VD>30	428,608	353,715	299,717	250,099	207,495	174,056	145,697	117,868	91,257

I Myocardial Infarction LHS

Myocardial Infarction cumul. incidence

— mean Vitamin D < 10ng/mL
— mean Vitamin D > 30ng/mL

HR = 1.25
CI [1.09 to 1.44]
$p = 0.001$

Time (years)

LHS Numbers at risk

VD<10	14,075	13,291	12,666	12,021	11,329	9,964	8,671	7,657	6,710
VD>30	14,258	14,080	13,880	13,621	13,303	12,114	10,926	9,875	9,001

J Myocardial Infarction TriNetX

Myocardial Infarction cumul. incidence

— Vitamin D < 10 ng/mL
— Vitamin D > 30 ng/mL

HR = 1.43
CI [1.39 to 1.46]
$p < 10^{-162}$

Time (years)

TriNetX Numbers at risk

VD<10	396,411	319,589	275,966	241,998	210,205	183,524	159,031	133,523	107,463
VD>30	401,390	329,957	278,602	231,469	191,325	159,277	132,079	105,426	80,469

K Heart Failure LHS

Heart Failure cumul. incidence

— mean Vitamin D < 10ng/mL
— mean Vitamin D > 30ng/mL

HR = 1.17
CI [1.04 to 1.32]
$p = 0.008$

Time (years)

LHS Numbers at risk

VD<10	14,415	13,611	12,969	12,309	11,600	10,217	8,885	7,850	6,890
VD>30	14,556	14,381	14,194	13,929	13,611	12,418	11,197	10,097	9,184

L Heart Failure TriNetX

Heart Failure cumul. incidence

— Vitamin D < 10 ng/mL
— Vitamin D > 30 ng/mL

HR = 1.42
CI [1.39 to 1.45]
$p < 10^{-270}$

Time (years)

TriNetX Numbers at risk

VD<10	385,784	305,697	263,970	231,478	201,068	175,547	152,119	127,719	102,792
VD>30	393,950	319,779	270,008	224,329	185,423	154,364	128,005	102,174	77,987

M Hemodialysis LHS

Dialysis cumul. incidence

— mean Vitamin D < 10ng/mL
— mean Vitamin D > 30ng/mL

HR = 2.11
CI [1.32 to 3.36]
$p = 0.001$

Time (years)

LHS Numbers at risk

VD<10	14,782	13,971	13,330	12,655	11,931	10,495	9,132	8,085	7,102
VD>30	14,778	14,625	14,456	14,210	13,903	12,698	11,467	10,399	9,474

N Hemodialysis TriNetX

Hemodialysis cumul. incidence

— Vitamin D < 10 ng/mL
— Vitamin D > 30 ng/mL

HR = 2.45
CI [2.34 to 2.55]
$p < 1 \times 10^{-308}$

Time (years)

TriNetX Numbers at risk

VD<10	402,782	329,146	284,219	249,235	216,491	189,012	163,787	137,516	110,677
VD>30	407,048	339,756	286,876	238,343	197,007	164,007	136,002	108,557	82,859

O Skin Malignancy LHS

Skin Malignancy cumul. incidence

— mean Vitamin D > 30ng/mL
— mean Vitamin D < 10ng/mL

HR = 0.47
CI [0.39 to 0.57]
$p < 10^{-13}$

Time (years)

LHS Numbers at risk

VD<10	14,739	13,921	13,281	12,598	11,867	10,429	9,073	8,041	7,055
VD>30	14,673	14,498	14,313	14,050	13,718	12,513	11,281	10,209	9,272

P Skin Malignancy TriNetX

Skin Malignancy cumul. incidence

— Vitamin D > 30 ng/mL
— Vitamin D < 10 ng/mL

HR = 0.69
CI [0.67 to 0.72]
$p < 10^{-94}$

Time (years)

TriNetX Numbers at risk

VD<10	405,603	331,485	286,238	251,006	218,029	190,355	164,951	138,493	111,463
VD>30	403,520	333,407	281,515	233,889	193,325	160,942	133,460	106,528	81,310

Figure 4: Independent Associations of Baseline Vitamin D Status and Supplementation with Major Health Outcomes

A Mortality

B Diabetes Mellitus

C Diabetic Retinopathy

D Myocardial Infarction

E Foot/Toe Amputation

F Skin Malignancy

Hazard ratios (HRs) with 95% confidence intervals (log scale) are shown for mortality and five clinical outcomes, based on multivariable Cox proportional hazards models adjusted for demographic and clinical covariates. Analyses include all Leumit Health Services (LHS) members aged ≥30 years with at least one serum 25(OH)D test performed since 2009; the test date serves as the baseline..

(A–F) Each panel presents the independent effects of:

- **Baseline serum 25(OH)D concentration**, categorized as 0–5, 5–10, 10–15, and 15–20 ng/mL, with >20 ng/mL serving as the reference category.
- **Vitamin D supplementation**, modeled as a time-dependent covariate based on pharmacy purchase data and estimated serum impact, grouped into predicted increases of 0.2–10, 10–20, and more thⱳn 20 ng/mL. The reference category includes time periods with no supplementation or an estimated effect <0.2 ng/mL.

HR < 1 indicates reduced risk; HR > 1 indicates increased risk. The vertical dashed line at HR=1 marks the null.

Significant and dose-responsive risk reductions are observed for mortality (A), diabetes mellitus (B), diabetic retinopathy (C), and myocardial infarction (D) with both higher baseline 25(OH)D and supplementation. Notably, even moderate supplementation (0.2–10 ng/mL equivalent) is consistently associated with reduced risk. Skin malignancy (F) shows an inverse association with baseline 25(OH)D levels, likely reflecting cumulative UV exposure, and there is no significant effect of supplementation.

Figure 4: Estimated 10-Year Number Needed to Treat (NNT) for Prevention of Mortality and Diabetes by Age, Baseline Vitamin D Status, and Supplementation Level

Each panel presents the estimated 10-year number needed to treat (NNT) to prevent one adverse event for a given category of vitamin D supplementation, stratified by baseline serum 25(OH)D levels (panel columns) and age group (rows: 30, 50, and 70 years). Supplementation categories are defined by the predicted increase in serum 25(OH)D concentration (ng/mL) and are represented by color-coded bars along the x-axis. Error bars indicate 95% confidence intervals. The wider intervals observed in the older age group for diabetes reflect the smaller number of new-onset cases beyond age 70, attributable to the limited number of individuals in this stratum, which reduces statistical power. Nonetheless, the overall trend closely parallels that observed in younger age groups.

Vitamin D supplementation was associated with markedly favorable NNTs for both all-cause mortality and incident diabetes mellitus, particularly among individuals with baseline 25(OH)D levels below 10 ng/mL. For all-cause mortality, NNTs decreased substantially with age, reaching values as low as 5 among older adults with baseline levels below 15 ng/mL—indicating a strong preventive benefit for the aging population.

For diabetes, NNTs remained relatively low and stable across all ages, suggesting that early intervention with vitamin D supplementation may be an effective strategy for diabetes prevention.